{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "Blood-brain barrier penetration", "Multi-function agents", "Naringenin-O-carbamate derivatives"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35065231", "DateCompleted": {"Year": "2022", "Month": "03", "Day": "22"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "22"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "01", "Day": "19"}], "Language": ["eng"], "ELocationID": ["10.1016/j.bmcl.2022.128574", "S0960-894X(22)00050-6"], "Journal": {"ISSN": "1464-3405", "JournalIssue": {"Volume": "60", "PubDate": {"Year": "2022", "Month": "Mar", "Day": "15"}}, "Title": "Bioorganic & medicinal chemistry letters", "ISOAbbreviation": "Bioorg Med Chem Lett"}, "ArticleTitle": "Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.", "Pagination": {"StartPage": "128574", "MedlinePgn": "128574"}, "Abstract": {"AbstractText": ["In this work, a series of naringenin-O-carbamate derivatives was designed and synthesized as multifunctional agents for the treatment of Alzheimer's disease (AD) through multi-target-directed ligands (MTDLs) strategy. The biological activity in vitro showed that compound 3c showed good antioxidant potency (ORAC\u00a0=\u00a01.0\u00a0eq), and it was a reversible huAChE (IC<sub>50</sub>\u00a0=\u00a09.7\u00a0\u03bcM) inhibitor. In addition, compound 3c significantly inhibited self-induced A\u03b2<sub>1-42</sub> aggregation, and it could activate UPS degradation pathway in HT22 cells and clear the aggregated proteins associated with AD. Moreover, compound 3c was a selective metal chelator, and it significantly inhibited and disaggregated Cu<sup>2+</sup>-mediated A\u03b2<sub>1-42</sub> aggregation. Furthermore, compound 3c displayed remarkable neuroprotective effect and anti-inflammatory property. Interestingly, compound 3c displayed good hepatoprotective effect by its antioxidant activity. More importantly, compound 3c demonstrated favourable blood-brain barrier penetration in vitro and drug-like property. Therefore, compound 3c was a promising multifunctional agent for the treatment of AD."], "CopyrightInformation": "Copyright \u00a9 2022 Elsevier Ltd. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China."}], "LastName": "Mi", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China."}], "LastName": "He", "ForeName": "Ying", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China."}], "LastName": "Yang", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China."}], "LastName": "Zhou", "ForeName": "Yi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Zhu", "ForeName": "Gaofeng", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Southwest Medical University, Luzhou 646000, China. Electronic address: wuanguo@swmu.edu.cn."}], "LastName": "Wu", "ForeName": "Anguo", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China. Electronic address: liuwm1969@163.com."}], "LastName": "Liu", "ForeName": "Wenmin", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang 473061, China. Electronic address: sangzhipei@126.com."}], "LastName": "Sang", "ForeName": "Zhipei", "Initials": "Z"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Bioorg Med Chem Lett", "NlmUniqueID": "9107377", "ISSNLinking": "0960-894X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amyloid beta-Peptides"}, {"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Carbamates"}, {"RegistryNumber": "0", "NameOfSubstance": "Cholinesterase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Flavanones"}, {"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Peptide Fragments"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Aggregates"}, {"RegistryNumber": "0", "NameOfSubstance": "amyloid beta-protein (1-42)"}, {"RegistryNumber": "789U1901C5", "NameOfSubstance": "Copper"}, {"RegistryNumber": "EC 3.1.1.7", "NameOfSubstance": "Acetylcholinesterase"}, {"RegistryNumber": "EC 3.1.1.8", "NameOfSubstance": "Butyrylcholinesterase"}, {"RegistryNumber": "HN5425SBF2", "NameOfSubstance": "naringenin"}], "MeshHeadingList": [{"QualifierName": ["metabolism"], "DescriptorName": "Acetylcholinesterase"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Amyloid beta-Peptides"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antioxidants"}, {"QualifierName": ["metabolism"], "DescriptorName": "Butyrylcholinesterase"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Carbamates"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Cholinesterase Inhibitors"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Copper"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Development"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Flavanones"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Peptide Fragments"}, {"QualifierName": ["drug effects"], "DescriptorName": "Protein Aggregates"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2021", "Month": "9", "Day": "22"}, {"Year": "2021", "Month": "12", "Day": "23"}, {"Year": "2022", "Month": "1", "Day": "15"}, {"Year": "2022", "Month": "1", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "22", "Hour": "20", "Minute": "9"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35065231", "10.1016/j.bmcl.2022.128574", "S0960-894X(22)00050-6"]}}], "PubmedBookArticle": []}